Mátyás Gábor, Alonso Sira, Patrignani Andrea, Marti Myriam, Arnold Eliane, Magyar István, Henggeler Caroline, Carrel Thierry, Steinmann Beat, Berger Wolfgang
Division of Medical Molecular Genetics and Gene Diagnostics, Institute of Medical Genetics, University of Zurich, Schorenstrasse 16, 8603, Schwerzenbach, Zurich, Switzerland.
Hum Genet. 2007 Aug;122(1):23-32. doi: 10.1007/s00439-007-0371-x. Epub 2007 May 10.
Mutations in the FBN1 gene are the major cause of Marfan syndrome (MFS), an autosomal dominant connective tissue disorder, which displays variable manifestations in the cardiovascular, ocular, and skeletal systems. Current molecular genetic testing of FBN1 may miss mutations in the promoter region or in other noncoding sequences as well as partial or complete gene deletions and duplications. In this study, we tested for copy number variations by successively applying multiplex ligation-dependent probe amplification (MLPA) and the Affymetrix Human Mapping 500 K Array Set, which contains probes for approximately 500,000 single-nucleotide polymorphisms (SNPs) across the genome. By analyzing genomic DNA of 101 unrelated individuals with MFS or related phenotypes in whom standard genetic testing detected no mutation, we identified FBN1 deletions in two patients with MFS. Our high-resolution approach narrowed down the deletion breakpoints. Subsequent sequencing of the junctional fragments revealed the deletion sizes of 26,887 and 302,580 bp, respectively. Surprisingly, both deletions affect the putative regulatory and promoter region of the FBN1 gene, strongly indicating that they abolish transcription of the deleted allele. This expectation of complete loss of function of one allele, i.e. true haploinsufficiency, was confirmed by transcript analyses. Our findings not only emphasize the importance of screening for large genomic rearrangements in comprehensive genetic testing of FBN1 but, importantly, also extend the molecular etiology of MFS by providing hitherto unreported evidence that true haploinsufficiency is sufficient to cause MFS.
FBN1基因突变是马凡综合征(MFS)的主要病因,马凡综合征是一种常染色体显性遗传性结缔组织疾病,在心血管、眼部和骨骼系统中表现出多种症状。目前对FBN1基因进行的分子遗传学检测可能会遗漏启动子区域或其他非编码序列中的突变,以及部分或完全的基因缺失和重复。在本研究中,我们通过连续应用多重连接依赖探针扩增技术(MLPA)和Affymetrix Human Mapping 500 K基因芯片组来检测拷贝数变异,该芯片组包含覆盖全基因组约50万个单核苷酸多态性(SNP)的探针。通过分析101名无亲缘关系、患有MFS或相关症状且标准基因检测未检测到突变的个体的基因组DNA,我们在两名MFS患者中发现了FBN1基因缺失。我们的高分辨率方法缩小了缺失断点的范围。随后对连接片段进行测序,结果显示缺失大小分别为26,887和302,580 bp。令人惊讶的是,这两个缺失均影响FBN1基因的假定调控区和启动子区,强烈表明它们消除了缺失等位基因的转录。转录分析证实了一个等位基因功能完全丧失的预期,即真正的单倍体不足。我们的研究结果不仅强调了在FBN1基因的全面基因检测中筛查大基因组重排的重要性,而且重要的是,还通过提供迄今未报道的证据扩展了MFS的分子病因,即真正的单倍体不足足以导致MFS。